Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience. (Q53262532)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21387357%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

title

Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21387357%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21387357%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Murat Özbalak

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21387357%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Nükhet Tüzüner

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21387357%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Burhan Ferhanoğlu

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21387357%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

author name string

Mustafa Cetiner

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21387357%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Huseyin Bekoz

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21387357%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Elif Birtas Atesoglu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21387357%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

Ayse Salihoglu

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21387357%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

publication date

8 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21387357%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

published in

Hematological Oncology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21387357%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21387357%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21387357%20AND%20SRC:MED&resulttype=core&format=json

24 January 2020

page(s)

76-81

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21387357%20AND%20SRC:MED&resulttype=core&format=json

Proposals for the classification of the myelodysplastic syndromes

24 January 2020

cites work

1 reference

5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia

21 January 2018

1 reference

Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference

21 January 2018

1 reference

7 January 2021

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

7 January 2021

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

7 January 2021

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

7 January 2021

Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes

1 reference

7 January 2021

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

1 reference

7 January 2021